Whalesbook
Tighter Rules for Pregabalin Sales
The Indian government has placed Pregabalin under Schedule H1 of the Drugs Rules, 1945. This change significantly tightens control over the drug to address its growing misuse. Pregabalin is used to treat nerve pain and seizures, but its sedative and euphoric effects have led to increasing abuse, particularly among young people seeking highs.
The decision followed recommendations from the Drugs Technical Advisory Board and warnings from state authorities. Previously, Pregabalin was under Schedule H, which allowed for more accessible sales.
New Pharmacy Requirements and Penalties
Under the new Schedule H1 status, Pregabalin can no longer be sold without a prescription. Pharmacies must now strictly verify prescriptions and keep detailed records of every Pregabalin sale. New packaging will feature a clear red "Rx" symbol and a "Schedule H1 Drug Warning" label.
The health ministry has instructed manufacturers, wholesalers, distributors, and pharmacists to follow these new rules immediately. Those who fail to comply, such as selling the drug without a prescription or failing to keep proper records, will face strict enforcement and penalties under the Drugs and Cosmetics Act, 1940.
Tackling Prescription Drug Abuse
This regulatory move aims to curb the illegal trade and abuse of Pregabalin. Reports from agencies like the Punjab Food and Drugs Administration have previously documented serious health issues, addiction, and large seizures of illegally held Pregabalin. The action is part of a wider effort to combat illicit drug activities and protect public health from the dangers of prescription drug misuse. Other countries are also increasing controls on medications with abuse potential. Regulators face the challenge of balancing access for legitimate patients with efforts to prevent diversion for illicit use.